FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Editorial Backs Post-Market Tests

[ Price : $8.95]

A Fort Wayne Gazette editorial backs Institute of Medicine drug safety recommendations, while a Washington Times commentary says t...

Review Period Set for Lyrica

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Warner-Lamberts Lyrica is 3,2789 days for the purpose of ...

FDA OKs IVX Animal Health ANADA

[ Price : $8.95]

Federal Register Final rule: FDA approves an IVX Animal Health ANADA for using amprolium solution to make medicated drinking water...

FDA, Duke Collaborating on Cardiac Safety

[ Price : $8.95]

FDA and Duke Clinical Research will look for gaps in cardiac biomarkers and prioritize research projects based on these needs.

More FDA Dirty Tricks Dept.: Investigation That Never Was

[ Price : $8.95]

For the second time in 24 hours, FDA's Department of Dirty Tricks surfaces in agency documents obtained under pretrial discovery ...

Senate Democrats Seek Hearing on Drug Safety Report

[ Price : $8.95]

Senate Democrats urge HELP Committee chair Mike Enzi (R-WY) to hold hearings on the recent Institute of Medicine drug safety repor...

FDA OKs Amgens Colon Cancer Drug

[ Price : $8.95]

FDA gives accelerated approval to Amgens Vectibix (panitumumab), indicated for treating colorectal cancer that has metastasized fo...

IoM Drug Safety Report Resonates with CDER

[ Price : $8.95]

CDER director Steven Galson says he is proud of the Centers drug safety efforts to date and will use a recent IoM report as an opp...

Review Period Set for Astellas Pharmas Mycamine

[ Price : $8.95]

Federal Register Notice: FDA determines the regulatory review period for Astellas Pharmas Mycamine.

CGMP Problems with Medex Anesthesia Sets

[ Price : $8.95]

A Cincinnati District Warning Letter says Medex, Inc., does not have marketing approval for its anesthesia and intravascular admin...